Details
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | 115484 |
| Seiten (von - bis) | 293–323 |
| Seitenumfang | 31 |
| Fachzeitschrift | DRUGS |
| Jahrgang | 85 |
| Frühes Online-Datum | 23 Jan. 2025 |
| Publikationsstatus | Veröffentlicht - März 2025 |
Abstract
The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of existing antibiotics, a lack of novel antibacterials entering the market, and an over- or misuse of existing antibiotics, which accelerates the evolution of resistant bacterial strains. This review focuses on innovative therapies by highlighting 19 novel antibacterials in clinical development as of June 2024. These selected compounds are characterized by new chemical scaffolds, novel molecular targets, and/or unique mechanisms of action, which render their potential to break antimicrobial resistance particularly high. A detailed analysis of the scientific foundations behind each of these compounds is provided, including their pharmacodynamic profiles, current development state, and potential for overcoming existing limitations in antibiotic therapy. By presenting this subset of chemically novel antibacterials, the review highlights the ability to innovate in antibiotic drug development to counteract bacterial resistance and improve treatment outcomes.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Pharmakologie (medizinische)
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: DRUGS, Jahrgang 85, 115484, 03.2025, S. 293–323.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Antibacterials with Novel Chemical Scaffolds in Clinical Development
AU - Heimann, Dominik
AU - Kohnhäuser, Daniel
AU - Kohnhäuser, Alexandra Jana
AU - Brönstrup, Mark
N1 - Publisher Copyright: © The Author(s) 2025.
PY - 2025/3
Y1 - 2025/3
N2 - The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of existing antibiotics, a lack of novel antibacterials entering the market, and an over- or misuse of existing antibiotics, which accelerates the evolution of resistant bacterial strains. This review focuses on innovative therapies by highlighting 19 novel antibacterials in clinical development as of June 2024. These selected compounds are characterized by new chemical scaffolds, novel molecular targets, and/or unique mechanisms of action, which render their potential to break antimicrobial resistance particularly high. A detailed analysis of the scientific foundations behind each of these compounds is provided, including their pharmacodynamic profiles, current development state, and potential for overcoming existing limitations in antibiotic therapy. By presenting this subset of chemically novel antibacterials, the review highlights the ability to innovate in antibiotic drug development to counteract bacterial resistance and improve treatment outcomes.
AB - The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of existing antibiotics, a lack of novel antibacterials entering the market, and an over- or misuse of existing antibiotics, which accelerates the evolution of resistant bacterial strains. This review focuses on innovative therapies by highlighting 19 novel antibacterials in clinical development as of June 2024. These selected compounds are characterized by new chemical scaffolds, novel molecular targets, and/or unique mechanisms of action, which render their potential to break antimicrobial resistance particularly high. A detailed analysis of the scientific foundations behind each of these compounds is provided, including their pharmacodynamic profiles, current development state, and potential for overcoming existing limitations in antibiotic therapy. By presenting this subset of chemically novel antibacterials, the review highlights the ability to innovate in antibiotic drug development to counteract bacterial resistance and improve treatment outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85217171895&partnerID=8YFLogxK
U2 - 10.1007/s40265-024-02137-x
DO - 10.1007/s40265-024-02137-x
M3 - Article
C2 - 39847315
AN - SCOPUS:85217171895
VL - 85
SP - 293
EP - 323
JO - DRUGS
JF - DRUGS
SN - 0012-6667
M1 - 115484
ER -